Dr. Marc Abrams brings 20 years of leadership experience in oligonucleotide therapeutics and targeted delivery of genetic medicines, most recently as CSO of Carbon Biosciences and SVP of Discovery Research at Dicerna Pharmaceuticals (a Novo Nordisk company). He has also held several roles of increasing responsibility at Merck and Co., Inc., and has served on SanegeneBio’s Scientific Advisory Board.